Enhanced uridine kinase in rat liver following 5-azacytidine administration. In vivo characterization and properties of partially purified enzyme.
D000311:Adrenal Glands / Q000502:physiology; D000818:Animals; D001374:Azacitidine / Q000008:administration & dosage / Q000494:pharmacology; D002474:Cell-Free System; D003562:Cytidine / Q000494:pharmacology*; D004247:DNA / Q000096:biosynthesis; D003609:Dactinomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D007274:Injections, Intraperitoneal; D008099:Liver / Q000201:enzymology*; D008297:Male; D009708:Nucleotidases / Q000378:metabolism; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D010770:Phosphotransferases / Q000302:isolation & purification / Q000378:metabolism*; D014176:Protein Biosynthesis; D012313:RNA / Q000096:biosynthesis; D051381:Rats; D013997:Time Factors; D014227:Triazines / Q000494:pharmacology*; D014500:Uracil Nucleotides / Q000096:biosynthesis; D014529:Uridine / Q000494:pharmacology
D014227:Triazines; D014500:Uracil Nucleotides; D003609:Dactinomycin; D003562:Cytidine; D012313:RNA; D004247:DNA; D010770:Phosphotransferases; D009708:Nucleotidases; D010744:Phosphoric Monoester Hydrolases; D001374:Azacitidine; D014529:Uridine